Thu, December 18, 2008
Wed, December 17, 2008
Tue, December 16, 2008
Mon, December 15, 2008
Sun, December 14, 2008
Fri, December 12, 2008
Thu, December 11, 2008
Wed, December 10, 2008
Tue, December 9, 2008
Mon, December 8, 2008
Sun, December 7, 2008
Sat, December 6, 2008
Fri, December 5, 2008
Thu, December 4, 2008
Wed, December 3, 2008
[ Wed, Dec 03rd 2008 ] - Market Wire
Protherics PLC: Offer Update
Tue, December 2, 2008
Mon, December 1, 2008
Sun, November 30, 2008
Fri, November 28, 2008
Thu, November 27, 2008
Wed, November 26, 2008
Tue, November 25, 2008
Mon, November 24, 2008
Thu, November 20, 2008

VIVUS To Participate in Obesity Panel at the 2008 RBC Capital Markets Healthcare Conference


//health-fitness.news-articles.net/content/2008/ .. 8-rbc-capital-markets-healthcare-conference.html
Published in Health and Fitness on Monday, December 8th 2008 at 5:00 GMT by Market Wire   Print publication without navigation


MOUNTAIN VIEW, Calif.--([ BUSINESS WIRE ])--VIVUS, Inc. (NASDAQ: VVUS), a pharmaceutical company dedicated to the development and commercialization of novel therapeutic products, today announced that Timothy Morris, vice president and chief financial officer of VIVUS, will be presenting at the RBC Capital Markets 2008 Healthcare Conference.

Mr. Morris will participate on a panel entitled, "Shrinking the Obesity Epidemic." The panel will take place at the Westin New York at Times Square, New York on Wednesday, December 10, 2008 at 11:00 a.m. ET. A live audio webcast of the presentation will be accessible for 30 days through the company's website at [ http://www.vivus.com. ]

About VIVUS

VIVUS, Inc. is a pharmaceutical company dedicated to the development and commercialization of novel therapeutic products. The current portfolio includes investigational products addressing obesity, diabetes and sexual health. The pipeline includes: Qnexa™, which is in phase 3 for the treatment of obesity and has completed a phase 2 study for the treatment of type 2 diabetes; avanafil, for which a phase 2 study has been completed for the treatment of erectile dysfunction (ED), and Luramist™ (Testosterone MDTS®), for which a phase 2 study has been completed for the treatment of Hypoactive Sexual Desire Disorder (HSDD). MUSE® is approved and currently on the market for the treatment of ED. For more information on clinical trials and products, please visit the company's web site at [ http://www.vivus.com ].


Publication Contributing Sources

Similar Health and Fitness Publications